Silverback Therapeutics, Inc. | Business Contracts

Executive Employment Agreement, by and between the Company and Brian T. Dorsey, effective as of October 1, 2018 (Filed With SEC on December 9, 2022)

Agreement and Plan of Merger and Reorganization, dated as of July 21, 2022, by and among Silverback Therapeutics, Inc., Sabre Merger Sub, Inc. and ARS Pharmaceuticals, Inc., as... (Filed With SEC on November 8, 2022)

Warrant to purchase stock issued to Silicon Valley Bank, dated as of September 30, 2019, as amended on December 7, 2020 (Filed With SEC on November 8, 2022)

License Agreement, dated as of June 18, 2018, by and between ARS Pharmaceuticals, Inc. and Aegis Therapeutics, LLC, as amended by the First Amendment to License Agreement, dated... (Filed With SEC on November 8, 2022)

Collaboration and License Agreement, dated as of April 30, 2020, by and between ARS Pharmaceuticals, Inc. and Alfresa Pharma Corporation (Filed With SEC on November 8, 2022)

Manufacturing Agreement, dated as September 9, 2020, by and between ARS Pharmaceuticals, Inc. and Renaissance Lakewood, LLC (Filed With SEC on November 8, 2022)

Second Amendment to Lease, dated September 27, 2022, by and between the Company and BMR-500 Fairview Avenue LLC (Filed With SEC on September 30, 2022)

Executive Employment Agreement, dated as of September 14, 2018, by and between ARS Pharmaceuticals, Inc. and Richard E. Lowenthal (Filed With SEC on November 8, 2022)

License and Supply Agreement, dated as of September 21, 2020, by and between ARS Pharmaceuticals, Inc. and Recordati Ireland, Ltd (Filed With SEC on November 8, 2022)

Collaboration and Distribution Agreement, dated as of March 1, 2021, by and between ARS Pharmaceuticals, Inc. and Pediatrix Therapeutics (Filed With SEC on November 8, 2022)

Executive Employment Agreement, dated as of February 9, 2022, by and between ARS Pharmaceuticals, Inc. and Kathleen Scott (Filed With SEC on November 8, 2022)

Executive Employment Agreement, dated as of September 14, 2018, by and between ARS Pharmaceuticals, Inc. and Dr. Sarina Tanimoto, as amended by Amendment No. 1 to Executive... (Filed With SEC on November 8, 2022)

Executive Employment Agreement, dated as of February 16, 2022, by and between ARS Pharmaceuticals, Inc. and Eric Karas (Filed With SEC on November 8, 2022)

Executive Employment Agreement, dated as of June 1, 2019, by and between ARS Pharmaceuticals, Inc. and Justin Chakma (Filed With SEC on November 8, 2022)

Consulting Agreement, dated as of April 26, 2021, by and between ARS Pharmaceuticals, Inc. and Brenton L. Saunders, as amended on April 25, 2022 (Filed With SEC on November 8, 2022)

Consulting Agreement, by and between ARS Pharmaceuticals, Inc. and Marlinspike Group, LLC, dated September 14, 2018 (Filed With SEC on November 8, 2022)

Consulting Agreement, by and between ARS Pharmaceuticals, Inc. and Pacific-Link Regulatory Consulting, Inc., dated July 1, 2022 (Filed With SEC on November 8, 2022)

Consulting Services Agreement and Statement of Work No. 1, by and between the registrant and Jonathan Piazza, dated September 2, 2022 (Filed With SEC on November 2, 2022)

Consulting Services Agreement and Statement of Work No. 1, by and between the registrant and Valerie Odegard, dated September 2, 2022 (Filed With SEC on November 2, 2022)

Consulting Services Agreement and Statement of Work No. 1, by and between the registrant and Laura Shawver, Ph.D., dated September 2, 2022 (Filed With SEC on November 2, 2022)

Second Amendment to the Agreement and Plan of Merger and Reorganization, dated October 25, 2022, by and among Silverback Therapeutics, Inc., Sabre Merger Sub, Inc. and ARS... (Filed With SEC on October 27, 2022)

Agreement and Plan of Merger and Reorganization, dated July 21, 2022, by and among Silverback Therapeutics, Inc., Sabre Merger Sub, Inc. and ARS Pharmaceuticals, Inc (Filed With SEC on July 21, 2022)

Form of Lock-Up Agreement, dated July 21, 2022 (Filed With SEC on July 21, 2022)

Form of ARS Pharmaceuticals, Inc. Support Agreement, dated July 21, 2022 (Filed With SEC on July 21, 2022)

Form of Silverback Therapeutics, Inc. Support Agreement, dated July 21, 2022 (Filed With SEC on July 21, 2022)

Non-Employee Director Compensation Policy, as amended (Filed With SEC on May 12, 2022)

Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the Silverback Therapeutics, Inc. 2020 Equity Incentive Plan (Filed With SEC on March 31, 2022)

SUBLEASE AGREEMENT (Filed With SEC on March 31, 2022)

Sublease, by and between the registrant and Delta Dental, dated July 1, 2021 (Filed With SEC on November 10, 2021)

Amendment No. 1 to Cell Line License Agreement, by and between the registrant and WuXi Biologics (Hong Kong) Limited, dated January 12, 2021 (Filed With SEC on March 29, 2021)

Description of Registrants Common Stock (Filed With SEC on March 29, 2021)

Silverback Therapeutics, Inc. 2020 Equity Incentive Plan, and Forms of Option Grant Notice, Option Agreement and Notice of Exercise thereunder (Filed With SEC on November 30, 2020)

Non-Employee Director Compensation Policy (Filed With SEC on November 30, 2020)

Silverback Therapeutics, Inc. 2020 Employee Stock Purchase Plan (Filed With SEC on November 30, 2020)

Form of Common Stock Certificate of the registrant (Filed With SEC on November 30, 2020)

Form of Underwriting Agreement (Filed With SEC on November 30, 2020)

Letter Agreement, by and between the registrant and Laura Shawver, Ph.D., dated March 6, 2020, as amended (Filed With SEC on November 10, 2020)

Silverback Therapeutics, Inc. 2016 Equity Incentive Plan, as amended, and Forms of Option Agreement, Notice of Exercise, Notice of Early Exercise, Restricted Stock Grant Notice... (Filed With SEC on November 10, 2020)

Warrant to purchase stock issued to Silicon Valley Bank, dated November 21, 2016 (Filed With SEC on November 10, 2020)

Form of Indemnity Agreement, by and between the registrant and its directors and officers (Filed With SEC on November 10, 2020)

Warrant to purchase stock issued to Silicon Valley Bank, dated December 22, 2017 (Filed With SEC on November 10, 2020)

Letter Agreement, by and between the registrant and Naomi Hunder, M.D., dated December 22, 2018 (Filed With SEC on November 10, 2020)

Letter Agreement, by and between the registrant and Valerie Odegard, Ph.D., dated July 23, 2016 (Filed With SEC on November 10, 2020)

Loan and Security Agreement, by and between the registrant and Silicon Valley Bank, dated November 21, 2016, as amended (Filed With SEC on November 10, 2020)

Letter Agreement, by and between the registrant and Jonathan Piazza, dated November 3, 2020 (Filed With SEC on November 10, 2020)

Lease, by and between the registrant and BMR-500 Fairview Avenue LLC, dated June 8, 2016 (Filed With SEC on November 10, 2020)

Master Laboratory Services Agreement, by and between the registrant and Q Squared Solutions LLC, dated May 25, 2020 (Filed With SEC on November 10, 2020)

Master Services Agreement, by and between the registrant and CE3, Inc., dated January 21, 2020 (Filed With SEC on November 10, 2020)

Cell Line License Agreement, by and between the registrant and WuXi Biologics (Hong Kong) Limited, dated October 11, 2019 (Filed With SEC on November 10, 2020)

Silverback Therapeutics, Inc. 2020 Change in Control and Severance Benefit Plan (Filed With SEC on November 10, 2020)

Amended and Restated Investors Rights Agreement, by and between the registrant and certain of its stockholders, dated September 22, 2020 (Filed With SEC on November 10, 2020)

Silverback Therapeutics, Inc. (51)